Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ)
CNY 44.61
(0.29%)
CNY 44.61
(0.29%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 2.48 Billion CNY | -34.6% |
| 2022 | 2.58 Billion CNY | 34.57% |
| 2021 | 1.91 Billion CNY | 70.98% |
| 2020 | 1.12 Billion CNY | 3.48% |
| 2019 | 1.08 Billion CNY | 82.03% |
| 2018 | 595.85 Million CNY | 42.95% |
| 2017 | 416.82 Million CNY | 110.58% |
| 2016 | 197.94 Million CNY | -7.35% |
| 2015 | 213.65 Million CNY | 26.08% |
| 2014 | 169.46 Million CNY | 66.04% |
| 2013 | 102.05 Million CNY | 41.84% |
| 2012 | 71.95 Million CNY | 30.67% |
| 2011 | 55.06 Million CNY | 59.48% |
| 2010 | 34.52 Million CNY | 320.52% |
| 2009 | 8.21 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 397.92 Million CNY | 8.96% |
| 2024 Q1 | 314.59 Million CNY | 6.17% |
| 2024 Q2 | 365.19 Million CNY | 16.08% |
| 2023 Q4 | 296.3 Million CNY | -58.45% |
| 2023 FY | 1.68 Billion CNY | -34.6% |
| 2023 Q1 | 630.89 Million CNY | 8.52% |
| 2023 Q2 | 967.7 Million CNY | 53.38% |
| 2023 Q3 | 713.12 Million CNY | -26.31% |
| 2022 Q2 | 826.53 Million CNY | 126.26% |
| 2022 FY | 2.58 Billion CNY | 34.57% |
| 2022 Q4 | 581.39 Million CNY | 15.03% |
| 2022 Q3 | 505.43 Million CNY | -38.85% |
| 2022 Q1 | 365.29 Million CNY | -73.06% |
| 2021 Q2 | 940.7 Million CNY | 24.38% |
| 2021 Q1 | 756.29 Million CNY | 12.25% |
| 2021 Q3 | 643.83 Million CNY | -31.56% |
| 2021 Q4 | 1.35 Billion CNY | 110.63% |
| 2021 FY | 1.91 Billion CNY | 70.98% |
| 2020 Q1 | 286.44 Million CNY | -32.54% |
| 2020 Q3 | 422.25 Million CNY | -49.72% |
| 2020 FY | 1.12 Billion CNY | 3.48% |
| 2020 Q4 | 673.73 Million CNY | 59.56% |
| 2020 Q2 | 839.87 Million CNY | 193.21% |
| 2019 Q4 | 424.63 Million CNY | 86.8% |
| 2019 FY | 1.08 Billion CNY | 82.03% |
| 2019 Q3 | 227.31 Million CNY | -8.67% |
| 2019 Q2 | 248.9 Million CNY | 35.44% |
| 2019 Q1 | 183.78 Million CNY | -8.19% |
| 2018 Q1 | 115.39 Million CNY | -2.94% |
| 2018 Q4 | 200.17 Million CNY | 66.24% |
| 2018 FY | 595.85 Million CNY | 42.95% |
| 2018 Q3 | 120.41 Million CNY | -24.68% |
| 2018 Q2 | 159.87 Million CNY | 38.55% |
| 2017 Q3 | 113.12 Million CNY | -1.24% |
| 2017 Q4 | 118.88 Million CNY | 5.08% |
| 2017 FY | 416.82 Million CNY | 110.58% |
| 2017 Q1 | 70.26 Million CNY | 22.09% |
| 2017 Q2 | 114.54 Million CNY | 63.01% |
| 2016 Q2 | 51.65 Million CNY | -0.21% |
| 2016 Q3 | 36.96 Million CNY | -28.43% |
| 2016 FY | 197.94 Million CNY | -7.35% |
| 2016 Q4 | 57.55 Million CNY | 55.69% |
| 2016 Q1 | 51.76 Million CNY | -7.48% |
| 2015 Q4 | 55.95 Million CNY | 9.1% |
| 2015 Q2 | 58.79 Million CNY | 23.46% |
| 2015 Q1 | 47.62 Million CNY | -9.14% |
| 2015 FY | 213.65 Million CNY | 26.08% |
| 2015 Q3 | 51.28 Million CNY | -12.78% |
| 2014 Q4 | 52.41 Million CNY | 12.75% |
| 2014 Q3 | 46.48 Million CNY | 24.51% |
| 2014 Q2 | 37.33 Million CNY | 12.37% |
| 2014 FY | 169.46 Million CNY | 66.04% |
| 2014 Q1 | 33.22 Million CNY | 42.93% |
| 2013 Q2 | 28.85 Million CNY | 15.23% |
| 2013 FY | 102.05 Million CNY | 41.84% |
| 2013 Q4 | 23.24 Million CNY | -6.73% |
| 2013 Q3 | 24.92 Million CNY | -13.62% |
| 2013 Q1 | 25.03 Million CNY | 18.39% |
| 2012 Q2 | 18.65 Million CNY | 22.6% |
| 2012 FY | 71.95 Million CNY | 30.67% |
| 2012 Q4 | 21.14 Million CNY | 24.83% |
| 2012 Q3 | 16.94 Million CNY | -9.16% |
| 2012 Q1 | 15.21 Million CNY | 12.55% |
| 2011 Q3 | 12.48 Million CNY | 0.0% |
| 2011 FY | 55.06 Million CNY | 59.48% |
| 2011 Q4 | 13.51 Million CNY | 8.25% |
| 2010 FY | 34.52 Million CNY | 320.52% |
| 2009 FY | 8.21 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 998.13 Million CNY | -149.16% |
| Dirui Industrial Co.,Ltd. | 296.87 Million CNY | -737.709% |
| Beijing Strong Biotechnologies, Inc. | 593.87 Million CNY | -318.764% |
| Medicalsystem Biotechnology Co., Ltd. | 279.11 Million CNY | -791.004% |
| Maccura Biotechnology Co.Ltd | 331.14 Million CNY | -651.013% |
| Guangzhou Wondfo Biotech Co.,Ltd | 549.13 Million CNY | -352.881% |
| Guangdong Hybribio Biotech Co.,Ltd. | 42.59 Million CNY | -5737.927% |
| BGI Genomics Co., Ltd. | 150.64 Million CNY | -1550.816% |
| Amoy Diagnostics Co., Ltd. | 301.24 Million CNY | -725.549% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -135.82 Million CNY | 1931.006% |